D
David R. Clemmons
Researcher at University of North Carolina at Chapel Hill
Publications - 390
Citations - 43379
David R. Clemmons is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Growth factor & Insulin-like growth factor-binding protein. The author has an hindex of 106, co-authored 387 publications receiving 41779 citations. Previous affiliations of David R. Clemmons include University of Texas Health Science Center at San Antonio & Sahlgrenska University Hospital.
Papers
More filters
Journal ArticleDOI
Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions*
J. I. Jones,David R. Clemmons +1 more
TL;DR: In recognition of its generalized pleiotypic actions, sulfation factor was renamed somatomedin (mediator of the effects of somatotropin) and was included in the emerging classification of broad spectrum growth factors along with platelet derived growth factor, fibroblast growth factors, and epidermal growth factor.
Journal ArticleDOI
Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline
TL;DR: GH therapy offers benefits in body composition, exercise capacity, skeletal integrity, and quality of life measures and is most likely to benefit those patients who have more severe GHD, and the risks associated with GH treatment are low.
Journal ArticleDOI
Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH research society
Kenneth M. Attie,Bengt-Åke Bengtsson,Sandra L. Blethen,Werner F. Blum,Fergus J. Cameron,Jean Claude Carel,Lena M. S. Carlsson,John J. Chipman,Jens Sandahl Christiansen,Peter E. Clayton,David R. Clemmons,Pinchas Cohen,Stenvert L. S. Drop,Kenji Fujieda,Ezio Ghigo,Raymond L. Hintz,Ken K. Y. Ho,Mbelenge Mapoko Ilondo,Hector Jasper,Bernd Jesussek,Anne Marie Kappelgaard,Zvi Laron,Barbara Lippe,Saul Malozowski,Primus E. Mullis,Sabine M P F de MuinckKeizer-Schrama,Yoshikazu Nishi,John S. Parks,Charlotte Phelps,Michael B. Ranke,Iain C.A.F. Robinson,Ron G. Rosenfeld,Susan R. Rose,Paul Saenger,Guissepe Saggese,Martin O. Savage,Stephen M Shalet,Pierre C. Sizonenko,Christian J. Strasburger,Katsuhiko Tachibana,Toshiaki Tanaka,Michael O. Thorner,Kerstin Albertsson Wikland,Zvi Zadik +43 more
Journal ArticleDOI
Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review
Journal ArticleDOI
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Peter J Trainer,W. M. Drake,Laurence Katznelson,Pamela U. Freda,Herman-Bonert,van der Lely Aj,Eleni V. Dimaraki,Paul M. Stewart,K. E. Friend,Mary Lee Vance,G. M. Besser,John A. Scarlett,Michael O. Thorner,Craig Parkinson,Anne Klibanski,Powell Js,Ariel L. Barkan,Michael C. Sheppard,Malsonado M,Rose Dr,David R. Clemmons,Gudmundur Johannsson,B.-Å. Bengtsson,Stavros Stavrou,David L. Kleinberg,David M. Cook,Lawrence S. Phillips,Martin Bidlingmaier,Christian J. Strasburger,Hackett S,Kenneth A. Zib,Bennett Wf,Robert J. Davis +32 more
TL;DR: Treatment of patients who have acromegaly with pegvisomant with a growth hormone–receptor antagonist results in a reduction in serum IGF-I concentrations and in clinical improvement.